IMPORTANT NOTICE: AATB Standards are subject to revision at any time pursuant to the Association’s procedures. Such revisions may consist of the addition of a new Standard, the rescission of an existing Standard, and/or the partial amendment of a Standard. Notice of each such revision is given by AATB by posting on the Association’s website, and distributing via email, a “Bulletin” that announces those changes and their respective effective dates. Persons seeking to determine the current provisions of Standards should always review the Bulletins for any such announcement of revisions to Standards or may request a current and effective copy of the Standards by sending a request to the AATB mailbox: email@example.com. Please contact AATB's headquarters office for any questions concerning Standards or revisions thereof.
Published on: February 22, 2021
Effective Mach 1, 2021, AATB will implement a new standards comment period to ensure that all proposed changes to the AATB Standards are broadly reviewed by AATB members before being presented to the AATB Board of Governors. The Standards Comment Period Policy (The Policy) will be added to the AATB Standards review process, as approved by the Standards Committee. This addition is intended to expand AATB individual member participation in the standards' revision process.
Published on: February 01, 2021
The Board of Governors acted on recommendation from the Standards Committee and, on December 18, 2020, approved changes to the 14th Edition (2016) of AATB's Standards for Tissue Banking (see below). These changes are announced in this Bulletin with a six-month implementation period starting on January 31, 2021. A redlined copy of the Standards Manual is attached to this Bulletin and disseminated to all Bulletin recipients to assist in the preparation process.
Published on: January 08, 2021
On January 5, the FDA notified the American Association of Tissue Banks (AATB) about its Safety and Availability Communication posted to the FDA website on January 4, 2021, titled “Updated Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the COVID-19 Pandemic”.
Published on: December 08, 2020
On December 7th 2020, the FDA updated their webpage titled Testing Human Cells, Tissues, and Cellular and Tissue Based Product (HCT/P) Donors for Relevant Communicable Disease Agents and Diseases.